
With more than 100 next-generation biologics set to lose patent exclusivity in the next 15 years, there is widespread agreement that developing biosimilars for these therapies will benefit society as a whole.
Kimberly Salgado is Head of Centre for Biosimilar Drug Development, ICON plc.

Published: June 17th 2025 | Updated: